Tonix Pharma Granted Up To $34 Mln 5-year DoD Contract For Antiviral Program Development
(RTTNews) - Tonix Pharmaceuticals Holding Corp. (TNXP) announced Monday it has been awarded an Other Transaction Agreement (OTA) with a potential for up to $34 million over five years by the Defense Threat Reduction Agency (DTRA), an agency within the U.S. Department of Defense (DoD).
The objective of the contract is to develop small molecule broad-spectrum antiviral agents for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments.
The $34 million five-year contract will help fund and accelerate the development of the Company's broad-spectrum antiviral program, which has the potential to reduce viral load and allow the adaptive immune system to alert the other arms of the immune system to mount a protective response.
Tonix will utilize its state-of-the-art research laboratory capabilities, including a Biosafety Level 3 (BSL-3) lab and an Animal Biosafety Level 3 (ABSL-3) facility at its research and development center (RDC) located in Frederick, Md., as well as experienced personnel in-house.
Tonix Pharma Granted U.S. Patent Covering TNX-1900 For Treatment Of Pain
DAX Firm Amidst Mixed Trends In Europe
Yen Rises Amid BoJ Rate Hike Bets
Asian Stocks Extend Gains
Yen Rises Against Majors
Europe Car Sales Increase In November
European Economic News Preview: German Import Price Data Due
